3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
5
Neoplasm Metastasis
2
Leukemia, Monocytic, Acute
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Advanced Cancer
1
Interventions
Fulvestrant
5
dalpiciclib
3
Letrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
exemestane
2
apatinib
2
Anastrozole
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liposomes
1
Irinotecan
1
Ga(III)-DOTATOC
1
Everolimus
1
Cell Separation
1
Capecitabine
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Breast Cancer Metastatic
×
Liposomes
×
Clear all
NCT03328884
2025-04-23
Phenomenal
MedSIR
Phase 2
Completed
55 enrolled